Alistair Strachan

Alistair Strachan has a wealth of work experience spanning from 1982 to the present. From 1982 to 1994 they worked at the South African Medical Research Council in R&D. From 1994 to 1998 they worked at South African Druggists as Group R&D Manager. From 1998 to 2000 they worked at Capricorn Pharmaceuticals Inc, Frederick, MD as COO. From 2000 to 2003 they worked at GlaxoSmithKline as Head of Operations Neurology and GI Centre of Excellence for Drug Discovery (CEDD), Harlow, UK. From 2003 to 2012 they worked at Pfizer in various roles, including Head of Operations Global Biotherapeutics Technologies, Head Discovery Research Operations UK & Site Head Wyeth Research Scotland (Aberdeen), Vice President & Head Global Business Development EMEA Region, Maidenhead, UK, and Head of Operations Discovery Research, Collegeville, PA. In 2012 they began working at the University of Aberdeen as an Honorary Professor. In 2012 they also began working at Fios Genomics Ltd as Non-Executive and Investors Director and later as Non Executive Chairman (Interim). In 2014 they began working at ILC Therapeutics Ltd as Co Founder and Investor. In 2015 they began working at RYBOQUIN COMPANY LTD as Non Executive Director & Board Member and Investor. Alistair also began working at Apitope International N.V. in 2012 as Consultant to the Board of Directors.

Alistair Strachan began their education in 1970, when they earned a BSc in Biochemistry with Pharmacology from the University of Strathclyde. Alistair continued their studies at the same university, receiving a PhD in Biochemistry, Immunology in 1979. In 1990, they attended Stellenbosch Business School, where they earned a BBA in Business Administration and an MBA in Business Administration in 1993.